Luzindole

Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity[1][2][3].

Product Specifications

CAS Number

[117946-91-5]

Product Name Alternative

N-0774

UNSPSC

12352005

Target

Melatonin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/luzindole.html

Purity

99.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(NCCC1=C(CC2=CC=CC=C2)NC3=C1C=CC=C3)=O

Molecular Formula

C19H20N2O

Molecular Weight

292.37

References & Citations

[1]Dubocovich ML, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355 (3) :365-75.|[2]Constantinescu CS, et al. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology. 1997;65 (4) :190-4.|[3]Dubocovich ML Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test. Eur J Pharmacol. 1990 Jul 3;182 (2) :313-25.